Mwandishi:
ULY CLINIC
Mhariri:
Dkt. Charles W, M.D
Jumapili, 28 Februari 2021
Ivermectin imethibitishwa kutibu COVID-19
Ivermectin, inayotumika kutibu maradhi ya vilemea mbalimbali, imeonekana katika tafiti kuwa na uwezo wa kuzuia usafirishaji wa protini muhimu zinazotengeneza kirusi, kuzuia kujishikiza kwa kirusi kwenye ukuta wa seli ya binadamu na kuzuia uzalishaji wa kemikali zinazoleta dalili kali za COVID-19.
Historia ya matumizi
Ivermectin ni dawa iliyopitishwa zamani na shirika la dawa amerika kwa ajili ya matibabu ya vimelea vya maradhi wanaosabanisha magonjwa ya upofu wa mtoni (onchocerciasis), minyoo helminthiases, na ugonjwa wa scabies
Virusi vinavyotibiwa na dawa hii
Kwa miaka ya karibuni dawa hii imeonekana kuwa na uwezo wa kutibu au kuzuia uzalianaji wa viini vinavyosababisha maradhi mbalimbali ambavyo;
SARS-CoV-2
Simian virus SV40
Dengue virus
West Nile Virus
Venezuelan equine encephalitis virus
Influenza
Pseudorabies virus
Zika virus
HIV
Tafiti nyingi zinaita kufanyika kwa tafiti zaidi kuona ni kwa namna gani dawa hii inaweza kufanya kazi kuzuia uzalishaji wa viini vya maradhi mbali na ile ya awali ya kutibu magonjwa yatokanayo na vimelea vya maradhi kama
Namna gani dawa hii inatibu ugonjwa wa COVID-19
Majaribio ya kisayansi yanayonyesha kuwa Ivermectin huzuia uzalishaji wa kirusi cha SARS-CoV-2 kinachosababisha COVID-19 kwa;
Kuzuia usafirishaji wa protini muhimu zinazotengeneza kirusi
Kuzuia kujishikiza kwa kirusi kwenye ukuta wa seli ya binadamu
Kuzuia uzalishaji wa kemikali zinazoongeza michomo ndani ya mwili
Matumizi
Namna ya kutumia dawa hii kwenye matibabu ya COVID 19, wasiliana na daktari wako
ULY CLINIC inakushauri siku zote uwasiliane na daktari wako kabla ya kuchukua hatua yoyote ile kiafya baada ya kusoma vidokezo hivi
Wasiliana na daktari wa ULY CLINIC kwa elimu na ushauri zaidi kupitia namba za simu au kubonyeza 'Pata Tiba' Chini ya tovuti hii.
Imeboreshwa,
19 Julai 2023, 20:41:21
Rejea za mada hii:
1. Leon Caly et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. https://www.sciencedirect.com/science/article/pii/S0166354220302011. Imechukuliwa 28.02.2021
2. Carlos Chaccour et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext. Imechukuliwa 28.02.2021
3. Ivermectin. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/. Imechukuliwa 28.02.2021
4. Omura S, et al. Ivermectin: panacea for resource-poor communities? Trends Parasitol. https://www.ncbi.nlm.nih.gov/pubmed/25130507. Imechukuliwa 28.02.2021
5. Fritz ML, et al. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s. Imechukuliwa 28.02.2021
6. Kircik LH, et al. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. https://www.ncbi.nlm.nih.gov/pubmed/26954318. Imechukuliwa 28.02.2021
7. Yang SNY, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res. 2020. https://www.ncbi.nlm.nih.gov/pubmed/32135219. Imechukuliwa 28.02.2021
8. Arévalo AP, et al. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. bioRxiv. 2020;Preprint. Available at: https://www.biorxiv.org/content/10.1101/2020.11.02.363242v1. Imechukuliwa 28.02.2021
9. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. https://www.ncbi.nlm.nih.gov/pubmed/32871846. Imechukuliwa 28.02.2021
10. Tay MY, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin. https://www.ncbi.nlm.nih.gov/pubmed/23769930. Imechukuliwa 28.02.2021